Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2B | P41595 | 5/20 | 0.34 |
| ▸ | RBP4 | P02753 | 2/20 | 0.33 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.33 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.32 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | JAK1 | P23458 | 1/20 | 0.32 |
| ▸ | TYK2 | P29597 | 1/20 | 0.32 |
| ▸ | JAK3 | P52333 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9894413 | 0.89 | APLNR (0.35) | — | |
| SCHEMBL1664606 | 0.83 | KDM4E (0.46) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL1662947 | 0.80 | RBP4 (0.37) | HTR2BRBP4EGLN1 | |
| SCHEMBL14782547 | 0.75 | HTR2B (0.38) | HTR2B | |
| SCHEMBL9894320 | 0.75 | HTR2B (0.38) | HTR2B | |
| SCHEMBL27669109 | 0.74 | HPGDS (0.39) | HTR2BRBP4EGLN1 | |
| SCHEMBL15732495 | 0.73 | P2RY14 (0.41) | HTR2BEGLN1 | |
| SCHEMBL1662538 | 0.73 | KDM4E (0.46) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL9894217 | 0.72 | HTR2B (0.36) | HTR2BJAK3 | |
| SCHEMBL6166219 | 0.71 | HTR2B (0.49) | HTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2491032-B1 | AKT INHIBITORS | LILLY CO ELI (US) | 2014-04-16 | — | — | EP | disclosed |
| US-8436002-B2 | AKT inhibitors | ELI LILLY AND COMPANY (US) | 2013-05-07 | — | — | US | disclosed |
| EP-2491032-A1 | AKT INHIBITORS | Eli Lilly and Company (US) | 2012-08-29 | — | — | EP | disclosed |
| US-20120149684-A1 | AKT INHIBITORS | ELI LILLY AND COMPANY (US) | 2012-06-14 | — | — | US | disclosed |
| WO-2011050016-A1 | AKT INHIBITORS | ELI LILLY AND COMPANY (US) | 2011-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149684-A1 | AKT INHIBITORS | AKT2, PIK3CA, AKT3 | HTR2B 3577/4885RBP4 4878/4885EGLN1 1678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.